Tariquidar

Drug Profile

Tariquidar

Alternative Names: XR 9576

Latest Information Update: 09 Aug 2007

Price : $50

At a glance

  • Originator Xenova Group
  • Developer QLT
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 03 Mar 2005 Phase-II clinical trials in Adrenal cancer in USA (IV)
  • 03 Mar 2005 Phase-II clinical trials in Cervical cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top